Posted by Michael Wonder on 17 Mar 2023
FDA approves dabrafenib with trametinib for paediatric patients with low grade glioma with a BRAF V600E mutation
16 March 2023 - Today, the FDA approved dabrafenib (Tafinlar, Novartis) with trametinib (Mekinist, Novartis) for paediatric patients 1 year of age and older with low-grade glioma with a BRAF V600E mutation who require systemic therapy.
The FDA also approved new oral formulations of both drugs suitable for patients who cannot swallow pills.
